Objective: cAMP and mature promoting factor (MPF) play critical roles during the matur ation of mammalian oocytes. The aim of this study was to produce the offspring from denuded oocytes (DOs) in mice by regulating cAMP and MPF. Methods: In this study, we used DOs at the germinal vesicle (GV) stage in mice and regulated levels of cAMP and MPF in DOs by adding Forskolin and PD166285 during in vitro matur ation without follicle stimulating hormone and luteinizing hormone, respectively. Results: Combined use of 50 μM Forskolin for 3 h and 2.5 μM PD166285 for additional 21 h enhanced the developmental competence of DOs, maturation rate of DOs was 76.71%± 4.11%, blastocyst rate was 18.33%±4.44% after parthenogenetic activation (PA). The DOs could successfully be fertilized with sperm in vitro, cleavage rate was 17.02%±5.82% and blastocyst rate was 5.65%±3.10%. Besides, 2cell in vitro fertilization embryos from DOs produced 4 normal live offspring (4/34).
INTRODUCTION
Pluripotent stem cells have unlimited selfrenewal capacity and plasticity to differentiate into all of the cell types even including sperm [1] and oocyte [2] under appropriate induction conditions. As a new kind of pluripotent stem cells reprogrammed from differentiated so matic cells, induced pluripotent stem (iPS) cells have already become a hot research topic in regenerative medicine. The related research about oocyte differentiation from iPS cells has opened up widespread applications in reproductive health and infertility in human be ings and speeded up breeding process in domestic animals [3] . However, the study confirmed that pluripotent stem cells can differentiate into artificial oocytes with reproductive function only under in vivo conditions [4] . Under in vitro conditions, the oocytes derived from pluri potent stem cells still stay in the early stages of meiotic process and cannot complete meiosis [5, 6] . In the process of oocyte differentiation from stem cells, stem cellderived oocytes in development mode are similar to Dos in vitro, so the related development research of DOs will improve induction and application of stem cellderived oocytes with reproductive func tion. Due to the lack of cumulus cells, stem cellderived oocytes and DOs have poor ooplasmic quality and low development competence [710] . With the help of cumulus cells, stem cell derived oocytes have high ooplasmic quality and development competence [11] .
During oocyte development, cAMP and MPF play a critical role in ooplasmic quality and development competence respectively [12, 13] . A high level of cAMP maintains oocyte arrest at the first meiotic prophase, under the condition of in vitro culture, transient increase of cAMP with Forskolin could induce meiotic resumption and increase maturation rate of DOs, but the DOs could not be performed in in vitro fertilization (IVF) [14] . PD166285 is a inhibitor of Myt1/Wee1B, Wee1B kinase is crucial to main tain G2 arrest through its inhibitory phosphorylation of cyclindependent kinases in cell cycles [1519] . Further study demonstrates that the inhibition of Myt1/Wee1B pathway caused by PD166285 is necessary for the activation of MPF [19] which also regulates meiotic resumption. Therefore PD166285 may also be beneficial for the development potential of DOs. According to mechanisms during oocyte maturation, the com bined application of Forskolin and PD166285 was carried out in a maturation process of DOs without an exogenous follic ular development hormone in current study.
MATERIALS AND METHODS

Ethics statement
All animal procedures were approved by the Animal Health Care Committee of Anhui Agricultural University in the study.
Animals and chemicals
Eightweekold female Institute of Cancer Research (ICR) mice were used in the study (Animal Research Center of Med ical University of Anhui, Anhui, China). All chemicals and regents used in this study were purchased from Sigma Chemi cal Company (Saint Louis, MO, USA) unless otherwise noted. Stock solutions of Forskolin (20 mM) and PD166285 (5 mM) were dissolved in dimethyl sulfoxide (0.1%). Stock solutions were diluted with SAGE In-Vitro Maturation Media (IVM) (CooperSurgical, Trumbull, CT, USA) when used.
Collection and in vitro maturation
Female mice without superovulation were sacrificed by cer vical dislocation, oocytes, including cumulusoocyte complex and DOs, were released from antral follicles by puncturing with needles, surging into oocyte washing media. Morphologi cally intact natural DOs arrested in GV stage with same size (>75 μm in diameter) were collected, washed twice and then cultured in maturation media with Forskolin or PD166285. The culture dishes were covered with mineral oil in a humidi fied atmosphere containing 5% CO 2 , at 37°C. The maturation of oocytes was determined on the basis of first polar body (PB1) morphology after 24 h maturation.
The whole experiment was divided into two parts: DOs were cultured in Forskolin at different concentrations (10 μM, 50 μM, 100 μM) for 3 h, 12 h, or 24 h, then transferred into ordinary culture media for additional period (21 h, 12 h, or 0 h). DOs cultured in the oocytes maturation media was served as a control group.
In our experiment, female mice, injected 10 IU pregnant mare serum gonadotropin (PMSG) and followed by 10 IU of human chorionic gonadotropin (HCG) 48 h after PMSG injection, were used to collect in vivo matured oocytes 17 h after HCG injection. For in vivo developed embryos, female mice, were injected PMSG and HCG and then mated with male mice, were used to collect the embryos 24 h after HCG injection.
Parthenogenetic activation
Matured DOs were incubated in activating media, Ca 2+ free CZB containing 10 mM SrCl 2 , for 2.5 h in a 5% CO 2 humidified incubator at 37°C. After twice washes, the DOs were transferred into G1 PLUS media (Vltrolife, Goteborg, Sweden). When developed into morulas, the embryos were transferred into G2 PLUS media (Vltrolife, Sweden) for the further develop ment. Embryos could be observed from the point when 20 h incubation was finished. The presumed embryos developed to 2cell stages were defined as activated DOs. The develop ment to morula and blastocyst stages were observed in about 2.5 d and 3.5 d after PA.
In vitro fertilization
Caudal epididymis from male ICR mice were washed twice in human tubal fluid (HTF) media (Vltrolife, Sweden), cut into pieces, dipped into the equilibrated HTF media for 10 min to release sperm, then the collected sperm were incubated in a tube for another 30 min at 37°C. Capacitated sperms in 3 to 5 μL supernatant were added on the periphery of the DOs collected previously in HTF media. After 6 h coculture, pre sumed zygotes were transferred into G1 PLUS media. The embryos were transferred into G2 PLUS media for further development when developed into morulas. Zygotes in 2cell stage would be observed after 24 h incubation. The develop ment to morula and blastocyst stages were observed in about 2.5 d and 3.5 d after IVF.
Embryo transfer
Female mice at estrus were placed with male mice in the ratio of 2:1, checked copulatory plugs in the following morning after mating, determined as day 0.5 dpc, and then 0.5 dpc pseudo pregnant female mice were anesthetized with 1% sodium pentothal. 2cell IVF embryos were transferred into the ovi ducts of 0.5 dpc pseudopregnant female mice.
Immunofluorescence
Matured DOs or blastocysts were fixed with 4% paraformal dehyde in vitro for 30 min, washed 3 times, 5 min each in phosphate buffered saline and permeabilized in 1% TritonX 100 for 15 min at room temperature. After washing 3 times, DOs were incubated in 1% bovine serum albumin for an hour, following by a whole night incubation in rabbit antiαTubulin (1:500, Abcam) or CDX2 antibody (1:100, Abcam) at 4°C. DOs were kept in Cyanine Dyes 3conjugated goatrabbit immu noglobulin G (1:200, Abcam) for an hour, washed thoroughly, then transferred into 1 μg/mL DAPI for 10 min. Coverslips were mounted when DOs were transferred into glycol on the glass slides. DOs were observed through the immunofluo rescencemicroscope (Olympus, Tokyo, Japan).
Statistical analysis
There were at least three replicates for each treatment. Data were analyzed with analysis of variance, a least significant difference (LSD) multiple comparison test was used to evaluate differences using SPSS17.0 (Chicago, IL, USA). Statistical sig nificance was considered to be at p<0.05. Data are presented as mean±standard error of the mean.
RESULTS
Morphological characteristics
In current study, GV stage DOs were cultured in maturation media supplemented with Forskolin and PD166285. GV stage DOs had normal size and shape and uniform cytoplasm and exhibited an intact GV with distinct nuclear membrane ( Figure  1A ). Matured DOs could reach morphological maturation and extruded PB1 24 h after IVMregardless of adding Forskolin or PD166285 in maturation media or not, and had no significant difference with in vivo mature oocytes in appearance ( Figure  1B, 1C) .
Effect of Forskolin and PD166285 on maturation
Forskolin has a cellintrinsic function in regulating oocyte maturation by activating adenylate cyclase to increase cAMP levels. In the IVM process, Forskolin had no significant effect on the survival of mouse DOs (Figure 2A) . In order to investi gate the effect of Forskolin on the maturation in mouse DOs, DOs were cultured in maturation media supplemented with Forskolin. We cultured GV stage DOs in maturation media containing 10, 50, and 100 μM Forskolin for 3 h, and then transferred the DOs in maturation media without Forskolin for additional 21 h, maturation rates of DOs were 53.64%± 1.42%, 50.73%±1.48%, and 54.68%±1.41% after 24 h incuba tion respectively. GV stage DOs in maturation media containing 10, 50, and 100 μM Forskolin were cultured for 12 h, and then additional 12 h, maturation rates were 49.39%±3.68%, 73.58% ±1.39%, and 49.85%±2.54%. When GV stage DOs in matura tion media containing 10, 50, 100 μM Forskolin were cultured for 24 h, maturation rates were 61.88%±2.14%, 48.60%±1.68%, and 56.23%±2.02% ( Figure 2B ). In addition, when cultured in maturation media containing Forskolin over 20 h, GV stage DOs spontaneously began to enter into meiosis and take on morphological maturation to extrude PB1.
PD166285 was described as a Wee1B kinase inhibitor to elevate MPF levels in oocytes [15] . We cultured GV stage DOs in maturation media containing 50 μM Forskolin for 3 h, and then transferred the DOs in maturation media with 2.5, 5, 10 μM PD166285 for additional 21 h, maturation rates were 76.55%±2.28%, 63.23%±13.26%, and 84.84%±1.44% ( Figure  2C ). In addition, the DOs in maturation media containing 50 μM Forskolin were cultured for 12 h, and then transferred in maturation media with 2.5, 5, and 10 μM PD166285 for addi tional 12 h, maturation rates were 73.27%±1.75%, 74.25%± 3.52%, and 73.73%±1.97% ( Figure 2D ). No significant differ ence was recognized in each experiment, this indicated that Forskolin and PD166285 did not significantly affect oocyte development and maturation in appearance.
Effect of Forskolin and PD166285 on parthenogenetic activation
We found that only adding Forskolin in the medium could facilitate the maturation in mouse DOs, but the matured DOs had a low development potential and failed to develop into blastocyst stage after PA, so we added PD166285 in the medi um to regulate the maturation of DOs. During IVM of DOs, we cultured GV stage DOs in maturation media containing 50 μM Forskolin for 3 h, and then transferred the DOs in ma turation media containing PD166285 for additional 21 h, the matured DOs in Forskolin and PD166285 groups could be activated, and activation rates were 42.66%±2.15% for 2.5 μM PD166285, 24.81%±2.66% for 5 μM PD166285 and 45.83%± 3.07% for 10 μM PD166285 ( Figure 3A) . Under maturation condition of 50 μM Forskolin for 12 h and PD166285 for ad ditional 12 h, activation rates were 69.76%±3.03% for 2.5 μM PD166285, 45.85%±1.94% for 5 μM PD166285 and 39.93%± 2.79% for 10 μM PD166285 ( Figure 3B ). In addition, the ma tured DOs in Forskolin for 3 h and PD166285 for additional 21 h groups could develop into blastocysts after PA, and blas tocyst rates were 18.11%±2.73% for 2.5 μM PD166285, 9.15% ±3.14% for 5 μM PD166285 and 2.94%±0.28% for 10 μM PD 166285 ( Figure 3C ). But the matured DOs could grow into blastocysts only from 2.5 μM PD166285 groups under mat uration condition of Forskolin for 12 h and PD166285 for additional 12 h, and blastocyst rate were 2.5%±0.24% (Fig  ure 3D) .
Effect of Forskolin and PD166285 on IVF
Under the condition of only adding Forskolin in maturation media or Forskolin for 12 h and PD166285 for additional 12 h, the matured DOs could not become competent to be fer tilized sperm in vitro. The matured DOs could be fertilized sperm to develop into embryos only under the condition of 50 μM PD166285 for 3 h and 2.5 μM PD166285 for additional 21 h. The embryos in an early stage had a highly symmetrical appearance and well developed into blastocysts ( Figure 4A  4D) , the cleavage rate was 17.02%±5.82% and blastocyst rate was 5.65%±3.11%. To further study the development poten tial in vivo of matured DOs treated with 50 μM Forskolin and 2.5 μM PD166285, 34 fertilized embryos in 2cell stage from matured DOs were transferred into fallopian tubes of surrogate mice by the transplantation of tubal umbrella. Four normal live pups (4/34) from mouse DOs were produced and had normal fertility ( Figure 4E ). 
Effect of Forskolin and PD166285 on spindle assembly
The formation of normal meiotic spindles during oocyte mat uration is very important to developmental potential. GV stage DOs in maturation media only containing Forskolin or with out Forskolin were cultured, and results showed that matured DOs (71/82) had loose chromosomes, irregular microtubules, asymmetrical spindle, and no obvious poles. GV stage DOs in maturation media containing 50 μM Forskolin for 3 h and 2.5 μM PD166285 for additional 21 h had matured DOs (83/94) that showed a similar spindle image with in vivo natural ma tured oocytes (92/102), mainly exhibited a symmetrical spindle, aggregated chromosomes at equatorial plate and consistent appearance of microtubules ( Figure 5 ), so the condition of 50 μM Forskolin for 3 h and 2.5 μM PD166285 for addition al 21 h is of great benefit to spindle assembly of mature DOs.
Effect of Forskolin and PD166285 on blastocyst quality
Blastocysts quality was further evaluated by cell counting. Dur ing IVM of DOs treated with Forskolin for 3 h and PD166285 for additional 21 h, the blastocysts from DOs by PA and IVF had a normal image and development potential. Blastocyst count showed that the total cell number in blastocysts from the DOs was 39.83±3.65 (Blastocyst number 51) and 39.67±
13.68 (Blastocyst number 72) after PA and IVF respectively, in vivoderived blastocysts about 41.67±9.53. The ratio of inner cell mass to total cell number was 32.39%±5.20% and 25.06% ±8.75% for PA and IVF blastocysts from the DOs respectively, in vivoderived blastocysts about 31.04%±4.07% by immuno fluorescence staining (Figure 6) . The difference between the groups of DOs and in vivoderived blastocysts was not sig nificant.
DISCUSSION
cAMP as a meiosis inhibitor regulates oocyte cytoplasmic maturation and enhances the quality of the cytoplasm through gap junctions of the surrounding cumulus cells and oocytes [8, 20] . It was found that the shortterm cAMP effect (cAMP pulsing) induced by adding Forskolin during IVM of DOs could improve maturation efficiency, but the developmental potential of DOs was not improved [14] . In this study, we simulated the changes of cAMP and MPF during oocyte mat uration, took advantage of the cAMP agonist Forskolin and MPF agonist PD166285 to regulate DOs during IVM, and established a simple maturation system in mouse DOs by regulating the level of cAMP and MPF in vitro. By adding 50 μM Forskolin for 3 h and 2.5 M PD166285 for additional 21 h during IVM, mouse DOs had a high development poten tial after PA and IVF embryos could develop to blastocyst in vitro and produce healthy newborn offspring in vivo. The high level of cAMP plays an important role to induce meiotic di vision arrest and cytoplasmic maturation and activate the cAMP/PKA pathway during oocyte maturation [21] . In cur rent study, we found that mouse DOs spontaneously extruded PB1 more than 20 h after the use of Forskolin during IVM. It shows that cAMP has an inhibitory timing effect on mouse DOs and other key factors also take part in the maturation and development with the cAMP. During the development of oo cytes, the level of intracellular cAMP was accompanied by the formation of microtubules and the maturation of nuclei, and the functional MPF was activated to promote the first meiotic division of oocytes [22, 23] . The experimental results also con firmed that mouse DOs treated only with Forskolin had no development potential in either parthenogenetic development or the fertilization with sperm. In fact, cAMP has a limited regulatory capacity in the process of meiosis and MPF is also involved in the regulation of meiosis [24, 25] . It is particularly important that MPF plays a key role in the process of oocyte 
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Control from the first meiotic division to the second meiotic division [26] . In the oocytes of the first meiotic prophase, MPF is pre sent in the form of low activity preMPF [27] . After the resumption of meiosis, the level of MPF increases rapidly, reaching the first peak in spindle formation, and promotes oocyte maturation [28] . In this study, the mature mouse DOs had IVF ability after treatment with transient Forskolin and then MPF agonist PD166285, and fertilized embryos from mouse DOs, like normal embryos, could develop into normal live offspring in vitro. It showed that mouse DOs had strong development potential and became functional oocytes after artificial regulation according to the law of oocyte develop ment, and the molecular mechanism and basic process of oocyte meiosis were also further confirmed by this model. In current study, we established a simple and efficient cul ture system for mouse DOs during IVM and laid an important foundation for producing artificial oocytes with reproduction function and focusing on meiosis mechanism by simulating in vivo cAMPMPF regulation in oocytes.
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